Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Medigene AG: Medigene participates at upcoming virtual conferences


Martinsried/ Munich (28.09.2020) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19.

 

Cell Therapy Manufacturing & Gene Therapy Congress

Date: 19 - 22 October

Website: https://informaconnect.com/celltherapy/

 

TCR Therapies Summit

Date: 26 - 29 October

Website: https://tcr-therapies-summit.com/

 

BIO-Europe Digital

Date: 26 - 29 October

Website: https://informaconnect.com/bioeurope/?gclid=EAIaIQobChMIn-75yv7b6wIVFed3Ch27uAezEAAYASAAEgLuufD_BwE

 

Neoantigen Based Therapies Summit

Date: 3 - 5 November

Website: https://neo-antigen.com/

 

35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)

Date: 9 - 14 November

Website: https://www.sitcancer.org/events/event-description?CalendarEventKey=bcb54b5c-c612-4e28-854f-0f8c41bca69f&Home=%2Fevents%2Fevent-description

 

62nd ASH Annual Meeting and Exposition

Date: 5 - 8 December

Website: https://www.hematology.org/meetings/annual-meeting

 

- end of announcement -

 

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

 

For more information, please visit http://www.medigene.com

 

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

 

Contact Medigene AG

Dr Gary Waanders, Dr Anna Niedl

Tel.: +49 89 2000 3333 01

email: investor@medigene.com

 

(end)

 

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg/Martinsried

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 3333 01

e-mail: investor@medigene.com

website: www.medigene.de

 

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

 

Medigene AG Stock

€3.80
-6.750%
Heavy losses for Medigene AG today as the stock fell by -€0.295 (-6.750%).
Currently there is a rather positive sentiment for Medigene AG with 5 Buy predictions and 1 Sell predictions.
With a target price of €8.00 there is potential for a 110.526% increase which would mean more than doubling the current price of €3.80 for Medigene AG.
Like: 0
Share

Comments